Search

everythinglearnresearchcommunity

for

Search:↓

Most clinicians follow discharge guidelines, many lupus patients don't use sunscreen regularly, dithranol is effective for psoriasis, biopsy methods should be based on lesion type, voriconazole may raise skin cancer risk, a new scale can help diagnose female hair loss early, and most melanomas may develop from existing moles.

The document concludes that various medications and treatments can have significant, sometimes adverse, effects on health outcomes.

The study found a link between the severity of Lichen Planopilaris seen by doctors and the details seen under a microscope, and created a new way to measure this severity.

A reliable severity score for female pattern hair loss was developed and validated.

Ritlecitinib improves hair regrowth in alopecia areata over 24 months.

Alopecia, especially androgenic, may increase cardiovascular risk, but more research is needed.

Finasteride's benefits outweigh its risks.

The Hair Check tool can measure hair loss, but patients' own reports are more reliable for assessing hair loss during chemotherapy.

Higher levels of small, dense LDL cholesterol are linked to a greater risk of heart attack in young adults.

Baricitinib, a drug for rheumatoid arthritis, atopic dermatitis, and alopecia areata, is generally safe with low risk of major side effects, even in patients with risk factors. It's also effective in promoting hair regrowth in alopecia areata patients.

Electron Beam Tomography (EBT) is a useful additional test to stress testing for detecting heart disease.

The Fatty Liver Index (FLI) may not be enough to rule out non-alcoholic fatty liver disease in lean women with polycystic ovary syndrome.

5-alpha-reductase inhibitors lower PSA density but higher PSA density indicates disease progression.

New scale reliably assesses male hair loss with female pattern.

Hair evaluation is crucial for early diagnosis and management of ARCI, as hair loss often indicates severity.

Finasteride and dutasteride reduce prostate cancer risk, but finasteride may increase higher-grade cancer risk.

Oral ritlecitinib and baricitinib are promising treatments for severe alopecia areata due to their balance of effectiveness and safety.

The study concludes that the new clinical scoring system is a quick, low-cost, and accurate method for diagnosing COVID-19.

The MPV/PC ratio can help assess disease activity in alopecia areata.

A scalp-cooling system effectively prevents hair loss in breast cancer patients treated with eribulin.

5-alpha reductase inhibitors slightly increase depression risk, but the risk varies based on the control group used.

Ritlecitinib and baricitinib are similarly effective for hair regrowth in severe alopecia areata.

The modified Sinclair scale effectively measures hair loss severity in men.

Certain inflammatory factors may increase or decrease the risk of developing PCOS.

Skin emergency severity rises with other health issues and affects multiple organs; a new grading system can improve patient care.

The care model improved timely diagnosis and treatment for psoriasis and psoriatic arthritis.

Ritlecitinib improved hair regrowth and emotional well-being in some alopecia areata patients.

Hematological ratios can effectively predict and manage alopecia areata severity.

Patients often overestimate their skin type, affecting sun protection and treatment plans.